Aurora kinase inhibitor
From Wikipedia, the free encyclopedia
Aurora kinase inhibitors are anticancer drugs that inhibit function of Aurora kinases[1]. Aurora kinases are overexpressed in many tumours. Three Aurora-kinase inhibitors have recently been described: ZM447439[2], Hesperadin[3] and VX-680[4].
[edit] References
- Nicholas Keen & Stephen Taylor, Aurora-kinase inhibitors as anticancer agents. Nature Reviews Cancer 4, 927-936 (2004)
- Hauf, S. et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. 161, 281–294 (2003).
- Ditchfield, C. et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 161, 267–280 (2003).
- Harrington, E. A. et al. VX-680, a potent and selective smallmolecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nature Med. 10, 262–267 (2004).
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
